Cannabis in the Arm: What Can we Learn from Intravenous Cannabinoid Studies?

Author(s): Amir Englund, James M. Stone, Paul D. Morrison

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 32 , 2012

Become EABM
Become Reviewer
Call for Editor


Cannabis is widely used recreationally and for symptomatic relief in a number of ailments. However, cannabis has been implicated as a risk factor for the development of psychotic illness. For forty years researchers have utilised intravenous preparations of Δ9- THC, as well as several other phytocannabinoids, in a laboratory setting. The intravenous route has the most reliable pharmacokinetics, reducing inter-individual variation in bioavailability and is well suited for the delivery of synthetic compounds containing a sole pharmacological moiety. Given the association between cannabinoids and psychotic illness, there has been a resurgence of interest in experimental studies of cannabinoids in humans, and the intravenous route has been employed. Here in a critical review, we appraise the major findings from recent intravenous cannabinoid studies in humans and trace the historical roots of this work back to the 1970’s.

Keywords: Cannabis, Intravenous, delta-9-tetrahydrocannabinol, delta-9-tetrahydrocannabivarin, cannabidiol, THC, psychotic illness, phytocannabinoids, pharmacokinetics, intravenous route.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [4906 - 4914]
Pages: 9
DOI: 10.2174/138161212802884618
Price: $65

Article Metrics

PDF: 30